(Q28363570)

1

0 references

L R Dolovich

2

0 references

B J O'Brien

3

0 references

A M Holbrook

4

0 references

A R Levy

Canadian Medical Association Journal

5

0 references

language of work or name

English

0 references

publication date

16 October 2001

0 references

published in

0 references

volume

165

0 references

issue

8

0 references

page(s)

1011-9

0 references

cites work

The strategic response by pharmaceutical firms to the Medicaid most-favored-customer rules

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=81535

Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting-enzyme inhibitors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=81535

Pharmaceutical reference prices. How do they work in practice?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=81535

What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=81535

Price regulation of pharmaceuticals in Canada

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=81535

Reference-based pricing in British Columbia: implications for cardiologists--an analysis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=81535

BC's reference-based pricing stirs controversy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=81535

The impact of reference pricing on clinical lipid control

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=81535

Opportunity lost: a frontline view of reference-based pricing

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=81535

Evaluating reference-based pricing: initial findings and prospects

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=81535

The Canadian Cardiovascular Society and reference-based drug pricing

27 November 2018

1 reference

12 December 2020

National patterns and predictors of beta-blocker use in patients with coronary artery disease

1 reference

12 December 2020

The change of cost: reference-based pricing and the statins

1 reference

12 December 2020

Thrombotic vascular events after change of statin

1 reference

12 December 2020

Thrombotic vascular events after change of statin

1 reference

12 December 2020

RE: M Thomas. The change of cost: reference-based pricing and the statins. 1999;15:535-8

1 reference

12 December 2020